Bot Image's prostate MRI AI software wins new clearance

By staff writers

March 28, 2023 -- MRI software developer Bot Image has secured an expanded clearance from the U.S. Food and Drug Administration (FDA) clearance for its ProstatID AI software.

The firm had received its initial FDA clearance in 2022 for the use of ProstatID in detection and diagnosis of prostate cancer on MRI. With the new additional clearance, ProstatID can also be used in prostate cancer screening on MRI and biparametric MRI, according to the vendor.

Copyright © 2023

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking